Por: CNBC Health January 18, 2023
watch nowVIDEO1:3901:39Moderna's phase three RSV trial found to be 83.7% effective in older adults on Tuesday said its vaccine that targets respiratory syncytial virus is effective at preventing disease in older adults.The vaccine was 83.7% effective at preventing lower respiratory tract disease, defined as two or more symptoms, in people ages 60 and older, according to the Boston biotech company. It was 82.4% effective at preventing lower... + full article
Time USA Health January 19, 2023
Moderna has become a well-known name thanks to its highly effective COVID-19 vaccine, based on mRNA technology. But even before the pandemic hit, the company was developing an mRNA-based vaccine against another scourge, respiratory syncytial virus (RSV), which primarily affects... + más
Moderna Says Its RSV Vaccine Trial Was a Success. A Clash With Pfizer and GSK Looms. | MarketWatch
RSV vaccine for older adults is 84% effective, Moderna says | Ars Technica
Ars Technica USA Science January 19, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 18, 2023 8:54 pm UTC Share this story Moderna's mRNA-based vaccine against RSV (respiratory syncytial (sin-SISH-uhl) virus) was effective at preventing disease in older adults, according to preliminary,... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
MarketWatch USA Business January 18, 2023
(ticker: MRNA) said Tuesday its experimental messenger RNA-based RSV vaccine, known as mRNA-1345, was 83.7% effective at preventing less severe disease in adults aged 60 and above, and 82.4% effective at preventing more severe disease. The company only released topline results,... + más
GSK vaccine for older adults granted FDA priority review | Fox Business
Pfizer rejects Moderna claim it copied Covid vaccine, accuses rival of rewriting history | CNBC
WPLG Local 10 USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals each fall.The preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be... + más
Strong RSV vaccine data lifts hopes after years of futility | ABC News
ABC7 USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.The preliminary results buoy hope that after decades of failure and frustration, vaccines... + más
Pfizer Says Its Maternal RSV Vaccine Can Protect Newborns From Severe Illness | NBC 6 South Florida
ABC News USA Health November 01, 2022
New research shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals with wheezing babies each fall.The preliminary results buoy hope that after decades of failure and frustration, against RSV may... + más
Strong RSV vaccine data lifts hopes after years of futility | WPLG Local 10
10 WBNS USA Health November 01, 2022
NEW YORK — shows vaccinating pregnant women helped protect their newborns from the common but scary respiratory virus called RSV that fills hospitals each fall. The preliminary results buoy hope that after decades of failure and frustration, vaccines against RSV may finally be... + más
About iurex | Privacy Policy | Disclaimer |